ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01715285
Recruitment Status : Active, not recruiting
First Posted : October 26, 2012
Last Update Posted : December 21, 2017
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : October 31, 2016
  Estimated Study Completion Date : August 3, 2021
  Certification/Extension First Submitted : November 20, 2017

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 March 9, 2018
 
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):